• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Jun18
Cyclo Therapeutics Advances NPC1 Phase III Clinical Trial
11:01
Jun11
Cyclo Therapeutics Completes Phase III Clinical Trial Recruitment for NPC Type C1
11:22
Apr24
Cyclo Therapeutics Completes Rare Genetic Disease Clinical Trial Recruitment
20:37
Nov15
Cyclo Therapeutics released FY2024 Q3 earnings on November 14 (EST), actual revenue 233.77 K USD (forecast 294 K USD), actual EPS -0.3074 USD (forecast -0.1566 USD)
04:00
Cyclo Therapeutics released FY2024 Cumulative 3Q Earnings on November 14 (EST), Revenue: 559.33K USD, EPS: -0.6693
04:00
Sep5
Cyclo Therapeutics Releases Preliminary Safety Data for Niemann-Pick Disease Type C1 Treatment
14:29

Schedules & Filings

Schedules
Filings
Nov14
Earning Release(EST)

FY2024 Q3 Earning Release (USD) Revenue 233.77 K, Net Income -8.833 M, EPS -0.3074

Aug14
Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 123.1 K, Net Income -5.981 M, EPS -0.2099

May15
Earning Release(EST)

FY2024 Q1 Earning Release (USD) Revenue 202.45 K, Net Income -4.343 M, EPS -0.1519

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
FJET
8.500
+136.77%
+4.910
AFJK
52.230
+100.81%
+26.220
DJTU
5.160
+83.63%
+2.350
ATHA
6.720
+62.52%
+2.585
SOC
8.250
+56.25%
+2.970
ZNB
1.020
+55.73%
+0.365
VIVK
0.0751
+47.25%
+0.024
SGD
0.2518
+42.26%
+0.075
DJT
14.860
+41.93%
+4.390
VSME
0.1035
+38.37%
+0.029
View More